NASDAQ:BIAF bioAffinity Technologies Q1 2026 Earnings Results & Report $3.52 -0.12 (-3.17%) As of 02:54 PM Eastern This is a fair market value price provided by Massive. Learn more. bioAffinity Technologies beat analyst earnings expectations but missed on revenue in its Q1 2026 results, released May 8, 2026. The company reported EPS of -$12.15 versus the -$36.00 consensus estimate, while revenue of $1.35 million fell short of the $1.48 million estimate by $0.13 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 8, 2026TimeBefore Market OpensConference Call8:30 AM ET bioAffinity Technologies EPS ResultsActual EPS-$12.15Consensus EPS -$36.00Beat/MissBeat by +$23.85One Year Ago EPSN/AEPS Beat Rate3 of last 7 quartersbioAffinity Technologies Revenue ResultsActual Revenue$1.35 millionExpected Revenue$1.48 millionBeat/MissMissed by -$131.47 thousandYoY Revenue GrowthN/AUpcoming EarningsbioAffinity Technologies' Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) bioAffinity Technologies Q1 2026 Earnings FAQ Did bioAffinity Technologies beat earnings estimates for Q1 2026? bioAffinity Technologies (NASDAQ:BIAF) reported earnings of -$12.15 per share for Q1 2026, beating the consensus estimate of -$36.00. The report was announced on Friday, May 8, 2026. What was bioAffinity Technologies' revenue for Q1 2026? bioAffinity Technologies reported revenue of $1.35 million for Q1 2026, against a consensus estimate of $1.48 million. When is bioAffinity Technologies' next earnings date? bioAffinity Technologies' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for bioAffinity Technologies on the company's earnings history page. bioAffinity Technologies Earnings HeadlinesbioAffinity to Present New Sputum-Based Lung Biomarker DataOctober 13 at 9:51 AM | tipranks.comBioAffinity Technologies Closes $4 Million Direct Offering, Private PlacementOctober 9, 2026 | finance.yahoo.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.October 14 at 1:00 AM | Porter & Company (Ad)bioAffinity Technologies Completes New $4 Million FinancingOctober 9, 2026 | tipranks.comWallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesOctober 9, 2026 | prnewswire.combioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesOctober 9, 2026 | businesswire.comSee More bioAffinity Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email. Email Address About bioAffinity TechnologiesbioAffinity Technologies (NASDAQ:BIAF) is a biotechnology company focused on developing diagnostic and therapeutic products for cancer and other diseases. The company’s technology platform uses porphyrin-based compounds designed to selectively interact with cancer cells, supporting applications in disease detection and treatment. Its lead diagnostic product, CyPath Lung, is a noninvasive urine-based test being developed to aid in the detection of lung cancer. The test is designed to use a porphyrin-based agent that interacts with abnormal cells in the lungs and can subsequently be detected in a urine sample. CyPath Lung has received Breakthrough Device designation from the U.S. Food and Drug Administration, although regulatory status and availability may vary by jurisdiction. bioAffinity Technologies is headquartered in Albuquerque, New Mexico, and serves the medical and biotechnology markets through the development of products intended to improve the early identification and treatment of cancer. The company is led by Maria Zannes, who serves as president and chief executive officer.View bioAffinity Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
